Cohen JB et al. Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: Safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN Study. ASH 2023;Abstract 981.

Dreyling M et al. Ibrutiinb combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): A three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet 2024;403(10441):2293-306. Abstract

Patel D et al. SOHO State of the Art Updates and Next Questions: Tailoring upfront therapy in mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 2023;23(9):633-41. Abstract

Wang ML et al. Acalabrutinib plus bendamustine and rituximab in untreated mantle cell lymphoma (MCL): Results from the phase 3, double-blind, placebo-controlled ECHO trial. EHA 2024;Abstract LBA3439.

Wang ML et al. Ibrutinib combined with venetoclax in patients with relapsed/refractory mantle cell lymphoma: Primary analysis results from the randomized phase 3 Sympatico study. ASH 2023;Abstract LBA-2.

Wang ML et al. Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol 2023;41(24):3988-97. Abstract

Wang ML et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med 2022;386(26):2482-94. Abstract